Chemical Biology & Drug Design · 2020 · 11 citations · 19 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryLead OptimizationAntibacterial AgentsAntibacterial PharmacologyAntimicrobial PeptidesEnzyme InhibitionPeptide Drug DiscoveryPeptidomimetic DesignCompetitive Binding InteractionsMinimum Inhibitory Concentration DeterminationMycobacterium Tuberculosis InfectionMycobacterium Tuberculosis PathogenesisPeptide Structure-activity RelationshipsPeptidomimetic Library SynthesisStructure-based PeptidomimeticsTuberculosis Drug Development
Emergence of MDR-TB and XDR-TB led to the failure of available anti-tubercular drugs. In order to explore, identify and develop new anti-tubercular drugs, novel peptidomimetic series of Mtb-peptide deformylase (PDF) inhibitors was designed and synthesized. In vitro antimycobacterial potential of compounds was established by screening of compounds against Mycobacterium tuberculosis H37Rv strain using MABA. Among them, ester series of compounds 4a, 4b, 4c, 4d, and 4e were found most active, with compound 4c being highly active and exhibiting minimum inhibitory concentration of 6.25 µg/ml against M. tb H37Rv strain. Additionally, the compounds were docked to determine the probable binding interactions and understand the mechanism of action of most active molecules on Mtb-peptide deformylase (PDF), which is involved in the mycobacterium protein synthesis.
19
Mariangela Biava, Giulio Cesare Porretta, Giovanna Poce et al. · Journal of Medicinal Chemistry · 2008 · 82 citations